Valneva (VALN) Expected to Post Quarterly Earnings on Thursday

Valneva (NASDAQ:VALN) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Valneva to post earnings of ($0.1887) per share and revenue of $44.17 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:00 AM ET.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.The company had revenue of $35.77 million for the quarter. On average, analysts expect Valneva to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Valneva Stock Performance

Valneva stock opened at $5.30 on Tuesday. The firm has a market cap of $502.92 million, a PE ratio of -2.83 and a beta of 1.77. Valneva has a 12 month low of $4.75 and a 12 month high of $12.25. The stock’s 50 day simple moving average is $5.21 and its two-hundred day simple moving average is $7.01. The company has a current ratio of 2.14, a quick ratio of 1.60 and a debt-to-equity ratio of 2.14.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Guggenheim set a $11.00 target price on shares of Valneva in a research note on Thursday, April 16th. Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Finally, The Goldman Sachs Group downgraded shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a research report on Wednesday, April 22nd. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Valneva currently has an average rating of “Hold” and an average price target of $11.97.

Institutional Trading of Valneva

A number of institutional investors and hedge funds have recently modified their holdings of VALN. Marex Group plc purchased a new stake in Valneva during the 2nd quarter valued at about $64,000. XTX Topco Ltd purchased a new position in Valneva in the 4th quarter worth approximately $94,000. Finally, JPMorgan Chase & Co. purchased a new position in Valneva in the 3rd quarter worth approximately $124,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.